Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Agile Therapeutics Inc    AGRX

AGILE THERAPEUTICS INC (AGRX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 01:46pm CET

PRINCETON, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26th, 2017 at 11:30 AM Eastern Time in New York City.

To access the live and archived webcast of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com.  The webcast will be archived on Agile Therapeutics website for 60 days following the event.

About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. Follow Agile on Twitter: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.

About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.

Contact: 
Mary Coleman - 609-683-1880
Investor Relations, Agile Therapeutics, Inc.

Primary Logo


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AGILE THERAPEUTICS INC
2017 BIOTECH MOVERS : Agile Therapeutics, Inc., (NASDAQ:AGRX) and GW Pharmaceuticals ..
2017 AGILE THERAPEUTICS : Receives a Complete Response Letter from the FDA for Twirla..
2017 AGILE THERAPEUTICS,INC. (NASDAQ : AGRX) Files An 8-K Other Events
2017 AGILE THERAPEUTICS : Receives a Complete Response Letter from the FDA for Twirla..
2017 AGILE THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form 8..
2017 Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for..
2017 AGILE THERAPEUTICS : Presents Additional Phase 3 SECURE Trial Results for Twirla..
2017 AGILE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
2017 AGILE THERAPEUTICS INC : Results of Operations and Financial Condition, Financia..
2017 AGILE THERAPEUTICS : reports 3Q loss
More news
News from SeekingAlpha
01/19 U.S. BIOTECH/PHARMA SECTOR DAILY OBS : Jan. 18, 2018
01/03 2018 BIOTECH INVESTING THEME : Looking For Safety Plays
2017 YOUR DAILY PHARMA SCOOP : Intercept Updates On NASH Trial, GW Pharmaceuticals Pr..
2017 YOUR DAILY PHARMA SCOOP : Portola BLA Review Process Delayed, DelMar Soars, Alex..
2017 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Agile CRL, Roche's Purchase, Mallinckrodt..
Financials ($)
Sales 2017 -
EBIT 2017 -28,7 M
Net income 2017 -30,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 0
Capi. / Sales 2018 14,2x
Capitalization 120 M
Chart AGILE THERAPEUTICS INC
Duration : Period :
Agile Therapeutics Inc Technical Analysis Chart | AGRX | US00847L1008 | 4-Traders
Technical analysis trends AGILE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 7,40 $
Spread / Average Target 111%
EPS Revisions
Managers
NameTitle
Alfred F. Altomari President, Chief Executive Officer & Director
Scott M. Coiante Chief Financial Officer & Vice President
Elizabeth Ijeoma Onyemelukwe Garner Chief Medical Officer & Senior Vice President
Abhijeet J. Lele Independent Director
William T. McKee Director
Sector and Competitors
1st jan.Capitalization (M$)
AGILE THERAPEUTICS INC30.11%120
GILEAD SCIENCES13.04%106 315
VERTEX PHARMACEUTICALS5.41%40 948
REGENERON PHARMACEUTICALS-1.18%40 382
GENMAB13.75%11 797
BIOVERATIV INC92.49%11 230